Current gene therapy for Duchenne muscular dystrophy (DMD) utilizes adeno-associated virus (AAV) to deliver miniaturized dystrophin (micro-dystrophin or μDys), which does not provide full protection for striated muscles as it lacks many important functional domains within full-length (FL) dystrophin. Here, DMD is linked to Duchenne muscular dystrophy.